Explore original, structured summaries for research and education.
Research profile
Selank
Selank is indexed as a Tuftsin analog research entry. Its current evidence category is Well Studied, and published discussion commonly places it within Cognitive, Longevity, Immune. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 751.89 Da
- Chain length
- 7 amino acids
- Type
- Tuftsin analog
- Reported half-life
- 2-10 minutes
Thr-Lys-Pro-Arg-Pro-Gly-ProLiterature map
Research indications
Anxiety
- Generalized Anxiety Disordermost effective
- Post-Traumatic Stress Disordereffective
- Social Anxietyeffective
Cognitive
- Memory Enhancementeffective
- Attention and Focuseffective
- Neuroprotectioneffective
Immune
- Immune Modulationmoderate
- Antiviral Activitymoderate
- Inflammation Regulationmoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for Selank. Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of Selank cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is Selank approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic NeurotransmissionSemenova TP, Kozlovskii II, Zakharova NM, Kozlovskaya MM · Frontiers in Pharmacology · 2016
- Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and NeurastheniaZozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008
- Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In VivoInozemtseva LS, Karpenko EA, Dolotov OV, et al. · Doklady Biological Sciences · 2008
- Experimental Optimization of Learning and Memory Processes by SelankSemenova TP, Kozlovskii II, Zakharova NM · Eksperimental'naia i Klinicheskaia Farmakologiia · 2010
- A Comparison of the Anxiolytic Effect and Tolerability of Selank and Phenazepam in the Treatment of Anxiety DisordersMedvedev VE, Tereshchenko ON, Kost NV, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2014